Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials

Fig. 1

Changes in efficacy parameters over time in patients with mildly reduced kidney function. A, Glycated hemoglobin (HbA1c). B, Fasting plasma glucose (FPG). C, Urine glucose-to-creatinine ratio (UGCR). D, Homeostasis model assessment of insulin resistance (HOMA-IR). The asterisks denote a statistically significant difference between the groups (*p < 0.05). LS, least squares

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840